Related Experiment Video
Updated: Oct 27, 2026
Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery
Published on: May 19, 2018
In vitro bioactivity profile-driven discovery of drug synergies in hepatocellular carcinoma
Tuan Xu1, Miao Xu1, Deborah K Ngan1
1Division of Pre-clinical Innovation, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Rockville, MD, 20850, USA.
Background:
Combination therapy is a central strategy to overcome drug resistance in hepatocellular carcinoma (HCC), yet systematic identification of synergistic combinations is constrained by the combinatorial search space.
Methods:
We developed a data-driven workflow to integrate two orthogonal single-agent resources for 244 drugs, including cell viability profiles across 11 liver cancer cell lines and bioactivity signatures across 1,925 biochemical and cell-based assays.
Results:
We calculated the correlation of the bioactivity profiles between each drug pair yielding 821 high-confidence combinations involving 190 unique drugs, from which eight anchors and a 125-drug library were selected by frequency-guided prioritization. Fixed-concentration screening of 992 anchor-library combinations in the Hep 3B2.1-7 cell line yielded 89 combinations with potency enhancement. Panobinostat showed the largest potency gains when combined with briciclib or thiocolchicine (69.5-fold and 81.1-fold lower IC₅₀, respectively). Matrix-based screening of these two representative combinations across 11 cell lines revealed pronounced concentration- and context-dependence. At optimal dose pairs, strong synergy was observed in Hep 3B2.1-7 (Zero Interaction Potency (ZIP) = 40.80 ± 4.22 with 58.53 ± 6.54% inhibition), whereas antagonism was observed in some cellular backgrounds.
Conclusion:
This label-free integration strategy reduces the experimental burden for hypothesis-driven combination discovery and provides context-specific preclinical leads for follow-up evaluation in HCC.
